Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not.
about
Advanced techniques using contrast media in neuroimagingMalignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methodsThe role of diffusion and perfusion weighted imaging in the differential diagnosis of cerebral tumors: a review and future perspectivesEmerging Techniques in Brain Tumor Imaging: What Radiologists Need to KnowThe basics of diffusion and perfusion imaging in brain tumorsMR Imaging Biomarkers in Oncology Clinical TrialsOutcome prediction in patients with glioblastoma by using imaging, clinical, and genomic biomarkers: focus on the nonenhancing component of the tumor.Genomic mapping and survival prediction in glioblastoma: molecular subclassification strengthened by hemodynamic imaging biomarkers.Optimized preload leakage-correction methods to improve the diagnostic accuracy of dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in posttreatment gliomasAZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients.Noninvasive detection of temozolomide in brain tumor xenografts by magnetic resonance spectroscopy.Pseudoprogression of glioblastoma after chemo- and radiation therapy: diagnosis by using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging with ferumoxytol versus gadoteridol and correlation with survival.Advanced MR imaging of gliomas: an updateAdvanced magnetic resonance imaging of the physical processes in human glioblastoma.Prognosis prediction of measurable enhancing lesion after completion of standard concomitant chemoradiotherapy and adjuvant temozolomide in glioblastoma patients: application of dynamic susceptibility contrast perfusion and diffusion-weighted imaginPitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immuno/targeted therapy - detecting illusive disease, defining response.ASFNR recommendations for clinical performance of MR dynamic susceptibility contrast perfusion imaging of the brain.pH-weighted molecular imaging of gliomas using amine chemical exchange saturation transfer MRIDiffusion, Perfusion, and Histopathologic Characteristics of Desmoplastic Infantile Ganglioglioma.Differentiation of Glioblastoma from Brain Metastasis: Qualitative and Quantitative Analysis Using Arterial Spin Labeling MR Imaging.Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumorsDifferentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imagingGlioblastoma: a method for predicting response to antiangiogenic chemotherapy by using MR perfusion imaging--pilot study.A subpopulation of cancer stem cells identifies radiographic characteristics in glioblastoma.Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma.Perfusion MRI of brain tumours: a comparative study of pseudo-continuous arterial spin labelling and dynamic susceptibility contrast imaging.A theoretical framework for determining cerebral vascular function and heterogeneity from dynamic susceptibility contrast MRIIntegrating diffusion kurtosis imaging, dynamic susceptibility-weighted contrast-enhanced MRI, and short echo time chemical shift imaging for grading gliomas.Assessment of therapeutic response and treatment planning for brain tumors using metabolic and physiological MRI.Dynamic Contrast-Enhanced MRI in Low-Grade Versus Anaplastic Oligodendrogliomas.Pretreatment blood-brain barrier damage and post-treatment intracranial hemorrhage in patients receiving intravenous tissue-type plasminogen activator.Susceptibility-based analysis of dynamic gadolinium bolus perfusion MRI.MRI-guided selection of patients for treatment of acute ischemic stroke.In vivo validation of MRI vessel caliber index measurement methods with intravital optical microscopy in a U87 mouse brain tumor model.Real-time diffusion-perfusion mismatch analysis in acute stroke.Differentiation of brain abscesses from glioblastomas and metastatic brain tumors: comparisons of diagnostic performance of dynamic susceptibility contrast-enhanced perfusion MR imaging before and after mathematic contrast leakage correction.Survival analysis in patients with newly diagnosed primary glioblastoma multiforme using pre- and post-treatment peritumoral perfusion imaging parameters.Arrival time correction for dynamic susceptibility contrast MR permeability imaging in stroke patientsEvaluation of a multiple spin- and gradient-echo (SAGE) EPI acquisition with SENSE acceleration: applications for perfusion imaging in and outside the brain
P2860
Q22252349-E9B16834-9583-47BE-BEEB-8206EAB6FEFCQ26853516-3BF6E9DC-5772-4683-BEA7-A719C70310C3Q27021359-2C6790DE-36E7-4532-B8D0-A8681E9AC940Q28068259-5ACA1E98-1710-4A9B-92B3-06BBC4B3FAF1Q28606582-162B4BB3-0B68-40E7-A14A-65B8672E5EBCQ30364608-10180545-DB81-4918-8864-C1D38201BE7DQ30405581-995AD794-F592-4ABF-949B-D95E4A43AE4DQ30414111-1121F7D8-2E1D-41B9-8A89-138F41624B29Q30419061-37A54117-763F-4AA2-B0AE-B28EF28D75A3Q30490422-FDF8D989-89F5-48DF-930F-071382924DE2Q30493217-E312D38E-F732-4DB1-98EA-3CCAA9F88DFBQ30496613-1E01B979-574A-455B-88B9-06EA0112FD7FQ30579847-C5B82A13-E416-4780-BF3D-58BBDA92D73CQ30655700-80E32D35-13B8-4A0A-9AAC-55959D58785BQ30847284-449CD81A-C968-445C-8E75-D4FECAB2BBEEQ30871297-0A807BFE-3389-4FB2-9C96-8CE9A9D75551Q30907831-ADCF8536-9F95-49CF-BEF5-BB19C93A3C0EQ30938805-F80D99C3-6741-4E09-BE88-9BD870F53EEFQ30976860-27A11B3A-4EA1-4AD5-B984-6FE0A786E764Q31137830-A0DFB8A8-BFF9-4C42-8070-3C098A766FF2Q31143153-98923B7F-7F17-4B9C-A3A6-5E81D4C9E53BQ33368027-C8B45E36-E550-48A7-8CEC-6317A2814555Q33507482-8AACA589-B5E2-4753-8E47-B0F8570FE4C5Q33562673-D95476E1-811E-42A0-B586-187762B58664Q33598907-90EF1BC4-054A-45F6-A0BF-8DE2075026F7Q33616589-CAA40E72-D7C8-4F90-AAC2-4E1B72C2EE95Q33718802-682F8067-3A06-4975-A85C-806472E21139Q33727635-B23210F2-3F64-46FC-AB01-8E3044404B0AQ33753445-D0686A11-0DAD-40A5-83D3-1D1F798065F8Q33888366-699D5E0F-8CA7-4012-8B11-1FA43D0F649BQ33904348-835CFB6F-104E-4054-8B05-246D649A1901Q33997366-1547DF1A-E80B-4409-BC36-8154BC1333B5Q34084696-F92F647B-4565-478D-8A53-EC7016CA9874Q34132045-218EA84E-C3BF-4520-AFF1-82CFDFF95F9DQ34132818-577A0890-2225-449A-BB31-85AAC25508C8Q34286188-DE13E8FF-3A56-47B1-BDBE-693641A743B3Q34361707-30672A09-8E12-4668-92FD-09DC9B1204CFQ34389144-9FC68DA3-22EC-4839-908D-8DC4A50CE0E2Q34534342-87A7BB52-01FE-4421-B7AD-709EA4AC93CEQ34619841-D30A8986-66DA-434F-9651-5CBBE9451CDC
P2860
Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Relative cerebral blood volume ...... ereas uncorrected maps do not.
@en
Relative cerebral blood volume ...... ereas uncorrected maps do not.
@nl
type
label
Relative cerebral blood volume ...... ereas uncorrected maps do not.
@en
Relative cerebral blood volume ...... ereas uncorrected maps do not.
@nl
prefLabel
Relative cerebral blood volume ...... ereas uncorrected maps do not.
@en
Relative cerebral blood volume ...... ereas uncorrected maps do not.
@nl
P2093
P1476
Relative cerebral blood volume ...... ereas uncorrected maps do not.
@en
P2093
Boxerman JL
Schmainda KM
Weisskoff RM
P304
P577
2006-04-01T00:00:00Z